PTC Therapeutics Email Format

Biotechnology Research
501-1,000 employees
South Plainfield, NJ, USA

PTC Therapeutics is a patient-centered biopharmaceutical company focused on discovering, developing, and commercializing medicines for children and adults living with rare and serious diseases.

Find contacts at PTC Therapeutics

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

firstinitiallast@ptcbio.com

Company Overview

Industry
Biotechnology Research
Founded
1998
Headquarters
South Plainfield, NJ, USA
Revenue
$500M-$1B
FUNDING Stage
Public
Key Executives
Matthew B. Klein (Chief Executive Officer), Pierre Gravier (Chief Financial Officer), Neil Almstead, Ph.D. (Chief Technical Operations Officer)

Tech Stack

New Relic

Infrastructure

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of PTC Therapeutics?

PTC Therapeutics uses the firstinitiallast format on ptcbio.com, so Jane Smith would be jsmith@ptcbio.com.

What are PTC Therapeutics' two main therapeutic areas?

PTC Therapeutics focuses its commercial and development efforts on neurology and metabolic conditions. Within those areas the company works on diseases such as Duchenne muscular dystrophy, AADC deficiency, Friedreich's ataxia, spinal muscular atrophy, and phenylketonuria.

Which gene therapy did PTC Therapeutics receive FDA approval for in November 2024?

The FDA approved Kebilidi (eladocagene exuparvovec-tneq) on November 13, 2024, making it the first FDA-approved gene therapy for AADC deficiency and available to patients at least 18 months of age and adults regardless of disease severity.

How does PTC Therapeutics generate royalty revenue from Evrysdi?

PTC Therapeutics co-developed Evrysdi (risdiplam) for spinal muscular atrophy through a collaboration with Roche and the SMA Foundation. Roche markets the drug globally, and PTC receives royalties on net sales, which totaled approximately 203.9 million dollars in 2024.

Where is PTC Therapeutics headquartered and does the company have international offices?

PTC Therapeutics is headquartered in South Plainfield, New Jersey, and maintains international operations through its international headquarters in Ireland, along with regional presence covering EMEA, Asia-Pacific, Canada, Brazil, and Latin America. If you need to reach a specific contact at PTC Therapeutics, Clay can help you find and verify the right person.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles